Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: Results of a multicenter, collaborative trial in Latin America
Jace. Silva et al., Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: Results of a multicenter, collaborative trial in Latin America, J CL PSYCH, 21(4), 2001, pp. 375-381
Conventional antipsychotic agents can induce extrapyramidal symptoms (EPS)
that may be alleviated by switching patients to novel agents such as olanza
pine. Patients with schizophrenia and related disorders (ICD-10) who were t
aking haloperidol (N = 94; mean dose = 12.7 mg/day) and had EPS (Simpson-An
gus Scale [SAS] > 3) were directly switched to 6 weeks of open-label olanza
pine treatment (mean dose = 11.4 mg/day). There were significant mean impro
vements (p < 0.001 for all measurements) from baseline to endpoint on the S
AS (-9.69 +/- 5.33; percentage change, 87.2%), the Barnes Akathisia Scale (
-1.00 +/- 1.19; percentage change, 82.5%), and the Abnormal Involuntary Mov
ement Scale (-1.48 +/- 2.89; percentage change, 81.1%), and anticholinergic
use decreased from 47.9% to 12.8% (mean baseline to endpoint change: -1.52
+/- 1.91-mg equivalents of benztropine; p < 0.001). Significant mean basel
ine to endpoint improvements (p <less than> 0.001 for all measurements) wer
e observed on the Positive and Negative Syndrome Scale (PANSS; -25.28 +/- 1
8.67; percentage change, 30.3%), the PANSS-extracted Brief Psychiatric Rati
ng Scale (0-6 scale, -13.41 +/- 10.16; percentage change, 54.4%), and the C
linical Global Impressions Severity scale (-1.16 +/- 1.19; percentage chang
e, 26.4%). Spontaneously reported treatment- emergent adverse events with a
greater than 5% incidence were somnolence (16.0%), increased appetite (14.
9%), weight gain (11.7%), headache (8.5%), anxiety (7.4%), dizziness (6.4%)
, and insomnia (5.3%). Criteria for a successful switch were met by 90.5% o
f patients. Psychotic symptom exacerbation was experienced by 30.9% of pati
ents at any time during the study and by 11.7% of patients at endpoint. Res
ults suggest that a direct switch to olanzapine is a therapeutic option whe
n patients with haloperidol-induced EPS are unable to tolerate a more gradu
al switch.